新辅助化疗后间隔减瘤手术是目前晚期上皮性卵巢癌（EOC）的常见治疗选择。标准化 CA-125 ELImination 速率常数 K (Std KELIM) 和铂类耐药复发 (PtRR) 评分已被提议作为肿瘤化疗敏感性的标志物。我们研究的目的是验证这些工具在现实世界接受新辅助化疗的晚期 EOC 患者群体中预测铂类敏感性。纳入了 2000 年至 2015 年间在居里研究所接受新辅助化疗的所有晚期 EOC 患者。 Std KELIM 是根据化疗前 100 天的 CA-125 浓度计算的。使用受试者工作特征（ROC）曲线分析、逻辑回归和校准曲线评估 Std KELIM 和 PtRR 评分对后续 PtRR 风险的预测价值。对铂类治疗的无治疗间隔 (TFIp) 和总生存期 (OS) 进行 Kaplan-Meier 生存分析。Std KELIM 数据适用于 149 名患者。 PtRR 的 AUC 为 0.67。根据单变量分析，低 Std KELIM 与 PtRR 显着相关（OR = 0.19（95% CI [0.06，0.53]，p = 0.002））。 PtRR 的校准曲线显示出对铂电阻概率的轻微但显着的低估 (p = 0.02)。单独良好的 Std KELIM (≥ 1) 以及与手术完整性相结合与 TFIp 和 OS 方面显着改善的生存相关。Std KELIM 是现实生活中化疗敏感性的早期预后标志物，与手术状态互补。它可以通过识别预后较差的患者来帮助临床医生对患者进行早期管理。© 2024。作者。

Neoadjuvant chemotherapy followed by interval debulking surgery is currently a common treatment option for advanced epithelial ovarian cancer (EOC). The Standardized CA-125 ELIMination rate constant K (Std KELIM) and the Platinum Resistant Recurrence (PtRR) Score have been proposed as markers of tumor chemosensitivity. The aim of our study was to validate these tools for predicting platinum sensitivity in a real-world population of patients with advanced EOC treated with neoadjuvant chemotherapy.All patients with advanced EOC treated with neoadjuvant chemotherapy at the Institut Curie between 2000 and 2015 were included. The Std KELIM was calculated with the CA-125 concentrations during the first 100 days of chemotherapy. The predictive value of Std KELIM and PtRR scores for the risk of subsequent PtRR was assessed using receiver operating characteristic (ROC) curve analysis, logistic regression and calibration curve. Kaplan-Meier survival analysis was performed for the treatment-free interval from platinum (TFIp) therapy and overall survival (OS).Std KELIM data were available for 149 patients. The AUC was 0.67 for PtRR. A low Std KELIM was significantly associated with PtRR (OR = 0.19 (95% CI [0.06, 0.53], p = 0.002)) according to the univariate analysis. The calibration curve of the PtRR showed a slight but significant underestimation (p = 0.02) of the probability of platinum resistance. Favorable Std KELIM (≥ 1) alone and combined with the completeness of surgery were associated with significantly better survival in terms of TFIp and OS.Std KELIM is an early prognostic marker of chemosensitivity in a real-life setting complementary to surgical status. It could help the clinician in the early management of patients by identifying those with a worse prognosis.© 2024. The Author(s).